Manning & Napier Group’s Amedisys AMED Stock Holding History

Manning & Napier Group’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-91,496	Closed	-$14.8M	–	271
2021 Q4	$14.8M	Buy	+91,496	New	+$14.7M	0.12%	152

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Manning & Napier Group's AMED Position: Q1 2022 in Review

Manning & Napier Group sold out of Amedisys (AMED) in Q1 2022, closing a stake of 91,496 shares — an estimated $14.8M sold.

Manning & Napier Group first reported a position in AMED in Q4 2021 and held it in 1 quarter. The position peaked at $14.8M in Q4 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

Manning & Napier Group reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
Manning & Napier Group sold 91,496 Amedisys shares in Q1 2022, an estimated $14.8M.
Manning & Napier Group first reported a position in Amedisys in Q4 2021 and held it in 1 quarter.
Manning & Napier Group's Amedisys position peaked at $14.8M in Q4 2021.
328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on Manning & Napier Group's 13F filing for Q1 2022, filed 19 Apr 2022.